Biological Psychiatry is pleased to announce that a new sibling journal, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging (BP:CNNI) will introduce its first issue in January 2016. The Editor of the new journal will be Cameron S. Carter, M.D., Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis.
BP:CNNI will provide an exciting new home for research in the areas of cognitive neuroscience and neuroimaging. Research in these areas is exploding. We hope that the new journal will capture both the innovation and the fundamental new insights into the relationships between brain and behavior emerging from the growth of this field. We hope that the new journal will represent the growing diversity of technologies (e.g., electroencephalography, magnetic resonance imaging) in this area. In addition, we expect that new strategies for image analysis, computational modeling, multimodal imaging, and other emerging research strategies (e.g., pharmaco-functional magnetic resonance imaging, imaging genomics) will yield deeper insights into the relationships between brain and behavior. Although Biological Psychiatry will continue to publish research in these areas, BP:CNNI will have greater flexibility to promote research in “pure” cognitive neuroscience, technical aspects of cognitive neuroscience and neuroimaging, and clinical applications.
The creation of BP:CNNI is in part an outgrowth of the success of Biological Psychiatry. As noted in our recent commentary (
1
), the substantial growth in submissions to Biological Psychiatry combined with limitations on the available page space have served to reduce the rate of acceptances to <10% of submissions. This has, in turn, somewhat reduced the scope of the journal to articles that have the highest impact (i.e., broadest interest) for translational neuroscience and experimental therapeutics. As editors, we have been increasingly frustrated by the need to reject wonderful articles because of space limitations.In addition to Dr. Carter, BP:CNNI will be led by Deputy Editors Deanna Barch, Ph.D., from Washington University in St. Louis (who will also become a Deputy Editor for Biological Psychiatry); Edward Bullmore, Ph.D., F.Med.Sci., from the University of Cambridge; Anissa Abi-Dargham, M.D., from Columbia University; and Murray Stein, M.D., M.P.H., from the University of California, San Diego. Ms. Rhiannon Bugno will serve as Managing Editor of BP:CNNI, as she does for Biological Psychiatry.
BP: CNNI will be receiving submissions in two ways. First, articles may be submitted directly to BP:CNNI via its Elsevier Editorial System website (currently being set up). In addition, selected excellent articles that are not accepted for publication in Biological Psychiatry will be offered the opportunity to be considered for publication in BP:CNNI. The new journal will be accepting articles in the same formats as Biological Psychiatry, i.e., Archival Reports of original research, Reviews, and Correspondence.
We are grateful to the leadership of the Society of Biological Psychiatry and to Elsevier for the opportunity to expand the breadth and impact of Biological Psychiatry through the creation of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. In creating the new journal, we look forward to working with a new community of authors and readers, our partners in the effort to advance science and alleviate human suffering. We hope that the members of the Society of Biological Psychiatry and the scientific community at large will find this new journal as exciting as we do, and we welcome your feedback and suggestions as we move forward.
Acknowledgments and Disclosures
JHK is a consultant for AbbVie, Inc, Amgen, Astellas Pharma Global Development, Inc, AstraZeneca, Biomedisyn Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc, and Neurovance, Inc, a subsidiary of Euthymics Bioscience, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Sage Therapeutics, Inc, Sunovion Pharmaceuticals, Inc, and Takeda Industries; is on the scientific advisory board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc, Naurex, Inc, and Pfizer Pharmaceuticals; is a stockholder in Biohaven Medical Sciences; holds stock options in Mnemosyne Pharmaceuticals, Inc; holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, U.S. Patent No. 5,447,948 (issued Sep 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued Jul 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression, U.S. Application No. 14/197,767 (filed Mar 5, 2014). CSC has consulted for Eli Lilly and Company, Hoffman-La Roche Inc, Merck, Pfizer Pharmaceuticals, and Servier; and has received research funding from GlaxoSmithKline.
Reference
- Biological Psychiatry: Raising the bar.Biol Psychiatry. 2013; 74: 476-477
Article info
Publication history
Published online: April 20, 2015
Accepted:
April 14,
2015
Received in revised form:
April 13,
2015
Received:
March 11,
2015
Identification
Copyright
Published by Elsevier Inc.
